Academic Journal
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
| Title: | Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer |
|---|---|
| Authors: | Van Cutsem, Eric, Collignon, Joëlle, Eefsen, Rikke L, Ochsenreither, Sebastian, Zvirbule, Zanete, Ivanauskas, Audrius, Arnold, Dirk, Baltruskeviciene, Edita, Pfeiffer, Per, Yachnin, Jeffrey, Magnusson, Susanne, Rydberg Millrud, Camilla, Sanfridson, Annika, Losic, Nedjad, Garcia-Ribas, Ignacio, Tersago, Dominique, Awada, Ahmad |
| Source: | Clin Cancer Res |
| Publisher Information: | American Association for Cancer Research (AACR), 2024. |
| Publication Year: | 2024 |
| Subject Terms: | Male, Pancreatic Neoplasms/pathology, Oncologie, Carcinoma, Pancreatic Ductal/drug therapy, Deoxycytidine, ACTIVATION, Deoxycytidine/analogs & derivatives, Pancreatic Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel/adverse effects, Human health sciences, Neoplasm Metastasis, Aged, 80 and over, CHEMORESISTANCE, Carcinoma, Pancreatic Ductal/immunology, Medicine (all), Middle Aged, Treatment Outcome, Oncology, Antibodies, Monoclonal, Humanized/adverse effects, Female, Pancreatic Neoplasms/immunology, Life Sciences & Biomedicine, Albumins/administration & dosage, Antibodies, Monoclonal, Humanized/administration & dosage, Carcinoma, Pancreatic Ductal, Adult, Paclitaxel, Clinical Trials: Targeted Therapy, Carcinoma, Pancreatic Ductal/pathology, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, POOR-PROGNOSIS, Paclitaxel/administration & dosage, 3211 Oncology and carcinogenesis, Albumins, Biomarkers, Tumor, Pancreatic Neoplasms/mortality, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Deoxycytidine/administration & dosage, Aged, Albumins/adverse effects, Science & Technology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, IL1RAP protein, human, 3202 Clinical sciences, 130-nm albumin-bound paclitaxel, Gemcitabine, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Interleukin-1 Receptor Accessory Protein, Deoxycytidine/therapeutic use |
| Description: | Purpose: IL1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL1 receptor accessory protein (IL1RAP)–targeting antibody with enhanced antibody-dependent cellular cytotoxicity that blocks IL1α/IL1β signaling. We investigated efficacy and safety of nadunolimab in PDAC, in combination with gemcitabine/nab-paclitaxel (GN). Patients and Methods: Patients with previously untreated locally advanced/metastatic PDAC received nadunolimab (1.0–7.5 mg/kg) every 2 weeks with standard GN. The primary objective was safety; secondary objectives were antitumor response, progression-free survival, and overall survival (OS). Correlations between serum and tumor biomarkers and clinical response were explored. Results: Seventy-six patients were enrolled; the median age was 63 years (range, 43–89), 42% were female, 97% had metastatic disease, and 9% had received adjuvant chemotherapy. The most frequent grade ≥3 adverse event was neutropenia (66%), typically during cycle 1. Infusion-related reactions occurred in 29% (grade 3, 3%). Only 1 of the 76 patients had grade 3 or above peripheral neuropathy. No marked dose-dependent differences in safety or efficacy were observed among the four dose groups. The median OS was 13.2 months (95% confidence interval, 11.0–15.6), and the 1-year survival rate was 58%. The median immune PFS (immune Response Evaluation Criteria in Solid Tumours) was 7.1 months (95% confidence interval, 5.2–7.4). Treatment efficacy was higher in patients with high versus low tumor baseline IL1RAP expression (OS 14.2 vs. 10.6 months; P = 0.012). A reduction in serum IL8 on treatment correlated with prolonged OS. Conclusions: Nadunolimab combined with GN shows promising efficacy and manageable safety in locally advanced/metastatic PDAC. Higher tumor baseline IL1RAP expression correlated with better outcome. |
| Document Type: | Article Other literature type |
| Language: | English |
| ISSN: | 1557-3265 1078-0432 |
| DOI: | 10.1158/1078-0432.ccr-24-0645 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/39385434 https://lirias.kuleuven.be/handle/20.500.12942/769085 https://doi.org/10.1158/1078-0432.ccr-24-0645 https://hdl.handle.net/2268/333840 https://doi.org/10.1158/1078-0432.CCR-24-0645 |
| Rights: | CC BY NC ND URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
| Accession Number: | edsair.doi.dedup.....fe06f836a151dfd67594e9e40a5edb5c |
| Database: | OpenAIRE |
| ISSN: | 15573265 10780432 |
|---|---|
| DOI: | 10.1158/1078-0432.ccr-24-0645 |